A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910
about
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.Nanoparticle Uptake: The Phagocyte ProblemProbing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthaseDiarylquinolines target subunit c of mycobacterial ATP synthaseInsights into the pharmacokinetic properties of antitubercular drugs.A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisThe chemical biology of new drugs in the development for tuberculosis.Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria.Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitorPhysiology of mycobacteriaBedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).A more robust version of the Arginine 210-switched mutant in subunit a of the Escherichia coli ATP synthase.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase.Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.A1Ao-ATP synthase of Methanobrevibacter ruminantium couples sodium ions for ATP synthesis under physiological conditionsType-II NADH Dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery.Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.A therapeutic connection between dietary phytochemicals and ATP synthase.A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.Bactericidal mode of action of bedaquiline.New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.Advances in the treatment of pulmonary tuberculosis.Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.Asymmetric Synthesis and Absolute Configuration Assignment of a New Type of Bedaquiline Analogue.Design and Stereochemical Research (DFT, ECD and Crystal Structure) of Novel Bedaquiline Analogs as Potent Antituberculosis Agents.Tomatidine, a lead antibiotic molecule that targets Staphylococcus aureus ATP synthase subunit C.Emerging drugs and drug targets against tuberculosis.Insights into the regulatory function of the ɛ subunit from bacterial F-type ATP synthases: a comparison of structural, biochemical and biophysical data.Determination of Absolute Configurations of Bedaquiline Analogs by Quantum Chemical Electronic Circular Dichroism Calculations and an X-ray Diffraction StudyChallenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
P2860
Q26824413-56494F8C-6B29-4912-95F2-76275A9D331AQ27342142-038908A7-068D-4476-A608-595E093A9F9AQ28395287-CCC9E9EC-6127-4AE8-93B4-0D8DFBD272B7Q28476612-681D1655-8F18-4A30-9C13-0E905FEC4200Q28486434-7364AC1A-99E3-423A-9FC2-036037B6F723Q30251497-2CFB7309-F6CC-4449-854C-F9119349DDF5Q33939074-B3033E2D-3779-4B9E-B283-B4DB06FAB697Q34054325-F978FCCC-6271-43CF-95C1-A77BF6A0158EQ34383371-572E15D7-EA3C-4F82-BFC5-7470F06952D1Q34901803-02FA0539-D243-4CEF-AD7A-4A5761889741Q36295358-04919711-3941-4FB2-A960-E429A6883E71Q37058451-89C1741B-B5C5-47A7-9495-D880186116EFQ37274952-BC7C47B3-39AC-4B6D-91A6-826E81BAADD7Q37312462-FB85B3F5-063F-4A83-AA0B-CA54FA8AFB74Q37346929-39E2D6BC-D1A0-44DC-BDC5-04E0BC4BA83AQ37358778-CF06C271-1E33-4150-8BA8-EAC8069CF906Q38190535-DD25AC19-E65B-4952-B174-D635957BF02BQ38995175-0ED36A3D-5AFD-4086-A87A-2CDC437B31D2Q39244025-C835485D-1E18-42D6-BF05-095762F4882AQ39284340-BE276473-4418-472A-802E-DEFDE462C51CQ39712350-9D5948B7-702B-49A9-93A4-46B9886EB4EDQ40083367-551595EC-EA2E-48ED-A322-F9EF6047128CQ41238712-AC968B54-6102-4452-AAB1-105DF4055533Q41441078-742CBB87-D3D8-4C9A-95E6-C00ED8BF9AC6Q41826050-461E5B7E-2090-45BD-9BE5-158CFFDA1908Q42355284-0930F0D8-D258-48EF-829A-E4106E124916Q42910136-20C48D37-09CF-448C-A81E-41CCD9A8B50BQ47446710-B0F4FEE6-5F9C-453E-9389-D0C1CBB02200Q51598159-26FE2260-602A-4F7B-95BB-916EC686A44FQ51659643-4EB9895B-0E12-48A4-8335-2E551553AD44Q52611994-BA6FA689-338F-457B-AB0A-77E9395F86A2Q53746587-01BA413B-36A6-4B71-AC03-4AD1DFDD596EQ53819039-BE5CEC9D-AD32-4E1F-BDF3-10DE4A52D169Q57075377-8A3C8914-8D09-4849-9A85-BFA9F6B2A5AFQ57656314-0B967036-EAC6-465D-8616-D52AA8EB6ED0
P2860
A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A computational model of the i ...... y a new drug candidate R207910
@ast
A computational model of the i ...... y a new drug candidate R207910
@en
A computational model of the i ...... y a new drug candidate R207910
@nl
type
label
A computational model of the i ...... y a new drug candidate R207910
@ast
A computational model of the i ...... y a new drug candidate R207910
@en
A computational model of the i ...... y a new drug candidate R207910
@nl
prefLabel
A computational model of the i ...... y a new drug candidate R207910
@ast
A computational model of the i ...... y a new drug candidate R207910
@en
A computational model of the i ...... y a new drug candidate R207910
@nl
P2093
P3181
P356
P1433
P1476
A computational model of the i ...... y a new drug candidate R207910
@en
P2093
Jérôme E G Guillemont
Koen Andries
Luc H M Koymans
Marc R de Jonge
P304
P3181
P356
10.1002/PROT.21376
P407
P577
2007-06-01T00:00:00Z